GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (FRA:J7Z) » Definitions » Total Noninterest Expense

Jazz Pharmaceuticals (FRA:J7Z) Total Noninterest Expense


View and export this data going back to 2007. Start your Free Trial

What is Jazz Pharmaceuticals Total Noninterest Expense?

Total Noninterest Expense only applies to banks.


Jazz Pharmaceuticals (FRA:J7Z) Business Description

Traded in Other Exchanges
Address
Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.